Wegovy Pill: Oral Semaglutide for Weight Management

Educational, not medical advice

This content is for general information only. It is not medical advice, a diagnosis, or a treatment plan. Beema Health's live clinical offering is telehealth medical weight-loss. Beema Health serves patients located in the United States only. It is not an international service. Licensed providers can evaluate adults in all 50 US states through telehealth. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. They are not the same as FDA-approved branded products. This library does not promise weight-loss results, show before-and-after photos, or collect health information.

What the Wegovy pill is

The Wegovy pill is oral semaglutide formulated for adult chronic weight management and for cardiovascular risk reduction in adults who already have cardiovascular disease plus overweight or obesity. The FDA approved the tablets in December 2025. They are taken once daily, not once weekly. Absorption of oral semaglutide is sensitive to food, other liquids, and other oral medicines, which is why the fasting and water-only rules are strict.

This page is educational. Beema Health does not sell Wegovy tablets. A prescription is required. Completing an online visit does not guarantee a prescription. No weight-loss outcome is guaranteed.

How to take Wegovy tablets

Take the tablet in the morning on an empty stomach with up to 4 ounces of water. Do not take it with coffee, juice, milk, or other liquids. Swallow the tablet whole. After swallowing, wait at least 30 minutes before eating, drinking anything other than the labeled water amount already taken, or taking other oral medications.

Skipping the wait or taking the tablet with breakfast can lower how much medicine is absorbed. That is a pharmacology issue, not a willpower issue. People who cannot follow fasting instructions may be better suited to an injectable presentation if a clinician recommends staying in the Wegovy family. That choice belongs to the prescriber and the patient.

Labeled tablet titration (not the OASIS 4 research strengths)

U.S. tablet strengths are 1.5 mg, 4 mg, 9 mg, and 25 mg. Table 2 of the current prescribing information uses 30-day steps: days 1-30 at 1.5 mg, days 31-60 at 4 mg, days 61-90 at 9 mg, then 25 mg daily from day 91 onward as maintenance for adult cardiovascular-risk reduction or weight reduction.

OASIS 4 used a different escalation ladder during the trial (including 3, 7, and 14 mg research steps before 25 mg). Do not copy a trial protocol from ClinicalTrials.gov if it disagrees with the FDA label in your hand. The labeled U.S. consumer product is 1.5 / 4 / 9 / 25 mg.

If 25 mg daily is not tolerated, the label allows considering a switch to Wegovy 1.7 mg injection weekly. If additional weight reduction is needed in adults with type 2 diabetes on 25 mg tablets, the label discusses moving to injection and following injection escalation. Those are labeled clinical options, not home experiments.

Days 1-30: 1.5 mg once daily
Days 31-60: 4 mg once daily
Days 61-90: 9 mg once daily
Day 91 onward: 25 mg once daily (recommended adult maintenance)

OASIS 4 in plain language

OASIS 4 was a randomized, double-blind, placebo-controlled trial of oral semaglutide 25 mg in adults without diabetes who had BMI of 30 or higher, or 27 or higher with at least one obesity-related complication. About 307 people were randomized 2:1 to active drug or placebo, with lifestyle intervention, for 64 weeks of treatment plus off-treatment follow-up.

Mean body-weight change at week 64 was about -13.6% with oral semaglutide and -2.2% with placebo. More people on active drug reached 5%, 10%, 15%, and 20% weight-reduction thresholds. Gastrointestinal adverse events occurred in about 74% on oral semaglutide versus about 42% on placebo. The trial supports efficacy of the 25 mg oral dose in a selected population. It does not guarantee those numbers in clinic, and it does not replace the boxed warning or contraindications.

Safety is still a GLP-1 safety profile

Wegovy tablets share the injection product's boxed warning on rodent thyroid C-cell tumors and the contraindications for MTC and MEN 2. Gastrointestinal effects, pancreatitis, gallbladder disease, dehydration-related kidney injury, hypersensitivity, and anesthesia aspiration risk still apply. Oral administration does not make the medicine 'gentle by default.'

Because other oral drugs must wait 30 minutes, clinicians should review the full medication list (including thyroid hormone, antibiotics, and other time-sensitive medicines). Pregnancy planning still requires a clinician conversation because semaglutide exposure in pregnancy is not recommended.

Rybelsus, other oral incretins, and Beema Health

Rybelsus is oral semaglutide for type 2 diabetes. Investigational oral GLP-1 receptor agonists such as orforglipron are separate molecules still discussed in the pipeline article in this library. None of those products is a Wegovy tablet.

Beema Health does not offer the Wegovy pill. If a Beema clinician prescribes for weight loss, it is compounded semaglutide when legally available and clinically appropriate, not Wegovy tablets. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. See the compounded semaglutide page. That is not a pitch that an oral Wegovy prescription will be issued.

Frequently asked questions

Is there an FDA-approved Wegovy pill?

Yes. In December 2025 the FDA approved Wegovy tablets (oral semaglutide) for specified adult uses: reducing excess body weight and maintaining weight reduction long term, and reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, always with diet and activity. It is a prescription medicine. Beema Health does not dispense Wegovy tablets.

How do you take the Wegovy pill?

Take one tablet by mouth once daily in the morning on an empty stomach with water only, up to 4 ounces. Swallow whole. Do not split, crush, chew, or dissolve. Wait at least 30 minutes before eating, drinking other beverages, or taking other oral medications. Food and other liquids reduce absorption.

What is the Wegovy tablet dose?

The U.S. label starts at 1.5 mg once daily for 30 days, then 4 mg (days 31-60), then 9 mg (days 61-90), then 25 mg daily as the recommended adult maintenance dose. If a step is not tolerated, escalation may be delayed. If 25 mg is not tolerated, the label discusses switching to Wegovy injection 1.7 mg weekly under clinician direction.

Is the Wegovy pill the same as Rybelsus?

No. Rybelsus is oral semaglutide approved for type 2 diabetes, with a different dose range (commonly 3, 7, and 14 mg in older formulations) and a diabetes indication. Wegovy tablets use 1.5, 4, 9, and 25 mg strengths for adult weight-reduction and cardiovascular-risk indications on the Wegovy label. Do not substitute one for the other without a prescriber.

What did OASIS 4 show?

OASIS 4 compared oral semaglutide 25 mg with placebo in adults with obesity, or overweight plus a comorbidity, without diabetes. Estimated mean weight change at week 64 was about -13.6% with oral semaglutide versus about -2.2% with placebo. Gastrointestinal adverse events were more common with active drug. Trial averages are not a promise of individual results.

Can I switch from Wegovy injection to the pill?

The prescribing information describes clinician-directed switches between 2.4 mg weekly injection and 25 mg daily tablets, including timing (for example, starting tablets one week after stopping 2.4 mg injection, or starting 2.4 mg injection the day after stopping 25 mg tablets). Those instructions are for the same branded product family, not a DIY conversion. Follow the current label and your prescriber.

Sources

Related education

Program pages

These pages describe Beema's live medical weight-loss offering. They are commercial pages, not this educational article.

Beema's live offering is medical weight-loss care

Licensed providers can evaluate adults in all 50 US states through telehealth. Beema Health serves patients located in the United States only. It is not an international service. A licensed clinician reviews each intake and decides whether any medication is appropriate. Completing an online intake does not guarantee a prescription. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate.

Beema Health is a LegitScript-certified website. Certification means the certified site is monitored against LegitScript's healthcare merchant standards. It is not an endorsement of Beema's products, not a statement that compounded medication is safe or FDA-approved, and not a claim about competitors. Beema Health has obtained Google's healthcare certification for prescription-drug advertising in the United States. That certification is about advertising eligibility. It is not a Google endorsement of Beema, of any medication, or of any clinical outcome.

Get Started

Wegovy pill (oral semaglutide) explained